Latest Funding News

Caravel Minerals reports substantial progress on its Definitive Feasibility Study for the Caravel Copper Project, advancing engineering, environmental approvals, and strategic partnerships toward development.

Riversgold has signed key Native Title agreements and a funding partnership to advance its Northern Zone Gold Project near Kalgoorlie, aiming for production in 2026.

Janus Henderson Investors has announced the distribution timetable for its Global Sustainable Equity Active ETF for the period ending December 2025, outlining key dates and reinvestment options for investors.

Latrobe Magnesium Limited has received a $6.29 million R&D tax rebate from the ATO, using the funds to reduce debt and progress its magnesium production plants in Australia and Malaysia.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Kinetiko Energy has secured approval to trade on the North American OTCQB Market, aiming to boost investor access and liquidity as it advances its South African gas projects.

American Tungsten & Antimony Ltd plans to unlock value by spinning out its Drummond Basin and NSW gold exploration assets into a new ASX-listed company, King Metals Limited, aiming to raise up to $6 million in an IPO.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Carnegie Clean Energy’s Spanish subsidiary has sold its 2025 Basque R&D tax deductions for €773,163, securing immediate funding to advance its ocean wave energy technology under the ACHIEVE Programme.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

Elevate Uranium Ltd has expanded its global uranium resource to 169 million pounds of U3O8 through the acquisition of the Napperby Uranium Project and complementary assets from Core Lithium Ltd. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.